The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease

Laura A. Bosmans; Lena Bosch; Pascal J.H. Kusters; Esther Lutgens; Tom T.P. Seijkens

doi:10.1007/s12265-020-09994-3

The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease

Laura A. Bosmans, Lena Bosch, Pascal J.H. Kusters, Esther Lutgens, Tom T.P. Seijkens

Cardiovascular Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Chronic inflammation drives the development of atherosclerosis. Despite optimal treatment of classical cardiovascular risk factors, a substantial portion of the population has elevated inflammatory biomarkers and develops atherosclerosis-related complications, indicating that a residual inflammatory risk drives atherosclerotic cardiovascular disease in these patients. Additional anti-inflammatory therapeutic strategies are therefore required. The co-stimulatory molecule CD40 and its ligand CD40L (CD154) have a central role in the regulation of the inflammatory response during the development of atherosclerosis by modulating the interaction between immune cells and between immune cells and non-immune cells. In this review, we discuss the role of the CD40-CD40L dyad in atherosclerosis, and we discuss recent studies on the therapeutic potential of novel CD40-CD40L targeting strategies in cardiovascular medicine.

Original language	English (US)
Pages (from-to)	13-22
Number of pages	10
Journal	Journal of cardiovascular translational research
Volume	14
Issue number	1
DOIs	https://doi.org/10.1007/s12265-020-09994-3
State	Published - Feb 2021

Keywords

Atherosclerosis
CD40
CD40L
Cardiovascular disease
Immune checkpoint proteins
Inflammation

ASJC Scopus subject areas

Molecular Medicine
Genetics
Pharmaceutical Science
Cardiology and Cardiovascular Medicine
Genetics(clinical)

Access to Document

10.1007/s12265-020-09994-3

Cite this

@article{145940b5a449449ca81777baceeec838,

title = "The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease",

abstract = "Chronic inflammation drives the development of atherosclerosis. Despite optimal treatment of classical cardiovascular risk factors, a substantial portion of the population has elevated inflammatory biomarkers and develops atherosclerosis-related complications, indicating that a residual inflammatory risk drives atherosclerotic cardiovascular disease in these patients. Additional anti-inflammatory therapeutic strategies are therefore required. The co-stimulatory molecule CD40 and its ligand CD40L (CD154) have a central role in the regulation of the inflammatory response during the development of atherosclerosis by modulating the interaction between immune cells and between immune cells and non-immune cells. In this review, we discuss the role of the CD40-CD40L dyad in atherosclerosis, and we discuss recent studies on the therapeutic potential of novel CD40-CD40L targeting strategies in cardiovascular medicine.",

keywords = "Atherosclerosis, CD40, CD40L, Cardiovascular disease, Immune checkpoint proteins, Inflammation",

author = "Bosmans, {Laura A.} and Lena Bosch and Kusters, {Pascal J.H.} and Esther Lutgens and Seijkens, {Tom T.P.}",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2021",

month = feb,

doi = "10.1007/s12265-020-09994-3",

language = "English (US)",

volume = "14",

pages = "13--22",

journal = "Journal of cardiovascular translational research",

issn = "1937-5387",

publisher = "Springer New York",

number = "1",

}

TY - JOUR

T1 - The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease

AU - Bosmans, Laura A.

AU - Bosch, Lena

AU - Kusters, Pascal J.H.

AU - Lutgens, Esther

AU - Seijkens, Tom T.P.

PY - 2021/2

Y1 - 2021/2

N2 - Chronic inflammation drives the development of atherosclerosis. Despite optimal treatment of classical cardiovascular risk factors, a substantial portion of the population has elevated inflammatory biomarkers and develops atherosclerosis-related complications, indicating that a residual inflammatory risk drives atherosclerotic cardiovascular disease in these patients. Additional anti-inflammatory therapeutic strategies are therefore required. The co-stimulatory molecule CD40 and its ligand CD40L (CD154) have a central role in the regulation of the inflammatory response during the development of atherosclerosis by modulating the interaction between immune cells and between immune cells and non-immune cells. In this review, we discuss the role of the CD40-CD40L dyad in atherosclerosis, and we discuss recent studies on the therapeutic potential of novel CD40-CD40L targeting strategies in cardiovascular medicine.

AB - Chronic inflammation drives the development of atherosclerosis. Despite optimal treatment of classical cardiovascular risk factors, a substantial portion of the population has elevated inflammatory biomarkers and develops atherosclerosis-related complications, indicating that a residual inflammatory risk drives atherosclerotic cardiovascular disease in these patients. Additional anti-inflammatory therapeutic strategies are therefore required. The co-stimulatory molecule CD40 and its ligand CD40L (CD154) have a central role in the regulation of the inflammatory response during the development of atherosclerosis by modulating the interaction between immune cells and between immune cells and non-immune cells. In this review, we discuss the role of the CD40-CD40L dyad in atherosclerosis, and we discuss recent studies on the therapeutic potential of novel CD40-CD40L targeting strategies in cardiovascular medicine.

KW - Atherosclerosis

KW - CD40

KW - CD40L

KW - Cardiovascular disease

KW - Immune checkpoint proteins

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=85082933178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85082933178&partnerID=8YFLogxK

U2 - 10.1007/s12265-020-09994-3

DO - 10.1007/s12265-020-09994-3

M3 - Review article

C2 - 32222950

AN - SCOPUS:85082933178

SN - 1937-5387

VL - 14

SP - 13

EP - 22

JO - Journal of cardiovascular translational research

JF - Journal of cardiovascular translational research

IS - 1

ER -

The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this